Evidence map›Paper›PMID 33747126›Full record

ArticleTherapeutic advances in gastroenterology2021

Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea.

Su Jin Choi, Soo Min Ahn, Ji Seon Oh, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park, Yong-Gil Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Su Jin ChoiDepartment of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Soo Min AhnDepartment of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Ji Seon OhDepartment of Information Medicine, Asan Medical Center, Seoul, South Korea.
Seokchan HongDepartment of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Chang-Keun LeeDepartment of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Bin YooDepartment of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Byong Duk YeDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.ORCID https://orcid.org/0000-0001-6647-6325
Suk-Kyun YangDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.ORCID https://orcid.org/0000-0003-2772-2575
Sang Hyoung ParkDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea.ORCID https://orcid.org/0000-0002-5366-5749
Yong-Gil KimDepartment of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea.
Ulsan College · KRAsan Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-tumor necrosis factor (TNF) agents are increasingly used for rheumatic diseases and inflammatory bowel disease (IBD), but are associated with the development of anti-TNF-induced lupus (ATIL). Nonetheless, few ATIL studies on non-Caucasian IBD patients exist. Here, we investigated the incidence, clinical features, and risk factors of ATIL in Korea.

methodsWe retrospectively reviewed the medical records of IBD patients undergoing anti-TNF therapy at our tertiary IBD center between 2008 and 2020. ATIL was diagnosed as a temporal association between symptoms and anti-TNF agents, and the presence of at least one serologic and non-serologic American College of Rheumatology criterion. The risk factors for ATIL occurrence were assessed using multivariate Cox regression analysis.

resultsOf 1362 IBD patients treated with anti-TNF agents, 50 (3.7%) ATIL cases were suspected, of which 14 (1.0%) received a definitive diagnosis. Arthritis and mucocutaneous symptoms were observed in 13 and 4 patients, respectively. All ATIL cases were positive for anti-nuclear and anti-dsDNA antibodies. Four patients (30.8%) improved while continuing anti-TNF therapy. At the final follow up, the ATIL group (

conclusionAlthough rare, ATIL is associated with poor treatment response to IBD in Korean patients. ATIL should be considered if arthritis and mucocutaneous symptoms develop during anti-TNF therapy for IBD.

Indexed as

anti-TNF agentdrug-induced lupusinflammatory bowel disease

Identifiers

PMID33747126
PMCPMC7940731
OpenAlexW3134447005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.